BSE · 539428
Tejnaksh Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹0 Cr — a 15.76% net margin, versus 28.25% the period before.
Shareholding
As of 2026-06-30
- Promoter73.83%
- Public26.17%
4,395 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #54 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,464 Cr | 61.06 | 13.55 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,01,088 Cr | 67.53 | 9.41 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,470 Cr | 100.73 | 5.75 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,667 Cr | 63.43 | 6.84 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,944 Cr | 172.58 | 15.91 | 8.48% | 6.54% |
| Global Health Limited | ₹38,978 Cr | 68.09 | 9.84 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,422 Cr | 44.57 | 8.47 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,378 Cr | 155.11 | 8.64 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,297 Cr | 57.42 | 12.88 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,605 Cr | 55.02 | 5.67 | 10.37% | 15.77% |
| Tejnaksh Healthcare Limited(this company) | ₹27 Cr | 22.1 | 1.01 | 4.52% | 11.48% |
AI analysis
AI-generated · google/gemini-2.5-flashTejnaksh Healthcare Limited is listed with a market capitalization of Rs 29 Cr. The company reported a revenue of Rs 13.3 Cr and a profit margin of 11.31%. Its debt-to-equity ratio stands at 0.12.
Positives
- +Promoter holding is high at 73.8331% as of June 30, 2026.
- +The debt-to-equity ratio is low at 0.12.
- +No promoter shares are pledged, with a promoter pledge of 0%.
Negatives
- −The trailing twelve months revenue of Rs 13.3 Cr is relatively low for its market capitalization of Rs 29 Cr.
- −No revenue growth percentage is available in the provided data.
- −The dividend yield is 0%, indicating no dividend payouts.
- −No quarterly results have been disclosed since March 2026.
- −Institutional shareholding (DII and FII) is 0% as of June 30, 2026.
Financial Performance
Tejnaksh Healthcare Limited's recent annual performance shows varying results. In March 2025, the company reported a revenue of Rs 2.4 Cr and a net profit of Rs 0.75 Cr. For the quarter ending March 2026, revenue was Rs 2.55 Cr with a net profit of Rs 0.36 Cr. The company's overall revenue for the trailing twelve months is Rs 13.3 Cr.
Profitability & Returns
The company recorded an EPS of 0.6 and a book value of Rs 13.36. The return on equity (ROE) is reported as 452.4%, while the return on capital employed (ROCE) is 6.3496%. The profit margin for Tejnaksh Healthcare Limited stands at 11.31%.
Balance Sheet
Tejnaksh Healthcare Limited maintains a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's book value per share is Rs 13.36. No dividend yield information is available as it is reported as 0%.
Ownership & Pledges
Public shareholding is recorded at 26.1669%. There is no promoter pledging reported, with promoter pledge at 0%.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Tejnaksh Healthcare Limitedshare price & fundamentals